Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Epizyme Inc (NQ: EPZM ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, Aug 11, 2022 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Epizyme Inc < Previous 1 2 3 4 5 Next > Epizyme: Q2 Earnings Insights August 09, 2022 Epizyme (NASDAQ:EPZM) reported its Q2 earnings results on Tuesday, August 9, 2022 at 06:00 AM. Here's what investors need to know about the announcement. Via Benzinga Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update August 09, 2022 From Epizyme, Inc. Via Business Wire EPIZYME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Epizyme, Inc. - EPZM July 12, 2022 From Kahn Swick & Foti, LLC Via Business Wire EPIZYME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Epizyme, Inc. - EPZM June 27, 2022 From Kahn Swick & Foti, LLC Via Business Wire Why Is Epizyme (EPZM) Stock Up 75% Today? June 27, 2022 EPZM stock is jumping higher today on news that Epizyme is being acquired by French pharmaceutical company Ipsen. Via InvestorPlace Why Epizyme Shares Are Soaring Today June 27, 2022 Epizyme Inc (NASDAQ: EPZM) shares are trading higher Monday after the company announced it entered into a definitive agreement to be acquired by Ipsen. Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2022 June 28, 2022 Upgrades Via Benzinga The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies June 27, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Global Pancreatic Cancer Therapeutics & Diagnostics Market Expected To Reach $5.6 Billion By 2027 June 28, 2022 Palm Beach, FL – June 28, 2022 – FinancialNewsMedia.com News Commentary – Pancreatic cancer therapeutics and diagnostics involve medical procedures used to diagnose pancreatic cancer and subsequent... Via FinancialNewsMedia Axsome Therapeutics (AXSM) Stock Soars on FDA Labeling Proposal June 27, 2022 Axsome Therapeutics (AXSM) stock is rising higher on Monday following an update from the FDA about product labeling for one of its drugs. Via InvestorPlace Benzinga's Top Ratings Upgrades, Downgrades For June 27, 2022 June 27, 2022 Upgrades Via Benzinga This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday June 28, 2022 Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) shares jumped 187.7% to close at $1.07 on Monday amid the Supreme Court overturning Roe V Wade. Via Benzinga Why Is NeuroSense Therapeutics Surging By 70%? 46 Stocks Moving In Monday's Mid-Day Session June 27, 2022 Gainers Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 87.3% to $0.6965 amid the Supreme Court overturning Roe V Wade. Via Benzinga EPZM Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Epizyme, Inc. Is Fair to Shareholders June 27, 2022 From Halper Sadeh LLP Via Business Wire 12 Health Care Stocks Moving In Monday's Pre-Market Session June 27, 2022 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday June 27, 2022 Good morning, trader! We're starting off the week with an overview of the biggest pre-market stock movers for Monday morning! Via InvestorPlace Ipsen Scoops Up Blood Cancer-Focused Epizyme - Read Why June 27, 2022 Ipsen SA (OTC: IPSEY) has Via Benzinga Epizyme + 20 Stocks Moving In Monday's Pre-Market Session June 27, 2022 Gainers Tenax Therapeutics, Inc. (NASDAQ: TENX) rose 90.1% to $0.59 in pre-market trading after dipping more than 46% on Friday. Via Benzinga Ipsen to acquire Epizyme, expanding its portfolio in oncology June 27, 2022 From Epizyme, Inc. Via Business Wire 76 Biggest Movers From Yesterday: Ocean Bio-Chem, Athira Pharma And More June 23, 2022 Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares climbed 117.2% to close at $12.86 on Wednesday after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash. Via Benzinga 40 Stocks Moving In Wednesday's Mid-Day Session June 22, 2022 Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares jumped 116.6% to $12.82 after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash. Via Benzinga 20 Stocks Moving in Tuesday's Pre-Market Session June 14, 2022 Gainers Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) rose 48.5% to $2.57 in pre-market trading after the company reached an agreement with Phillip Morris for international electronic nicotine... Via Benzinga 93 Biggest Movers From Yesterday June 14, 2022 Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in... Via Benzinga 91 Biggest Movers From Friday June 13, 2022 Gainers RISE Education Cayman Ltd (NYSE: REDU) shares jumped 138.5% to settle at $3.41 on Friday. RISE Education announced expected timing for the completion of the merger with Dada Auto. Via Benzinga 44 Stocks Moving In Friday's Mid-Day Session June 10, 2022 Gainers Cogent Biosciences, Inc. (NASDAQ: COGT) shares jumped 77% to $8.79 after the company reported initial data from its ongoing Phase 2 APEX clinical trial. Via Benzinga 25 Stocks Moving in Friday's Pre-Market Session June 10, 2022 Gainers Regis Corporation (NYSE: RGS) rose 74.4% to $0.9753 in pre-market trading. Regis partnered with salon technology provider Zenoti to support its 5,000+ locations. Via Benzinga Epizyme's Return On Capital Employed Insights June 09, 2022 Epizyme (NASDAQ:EPZM) brought in sales totaling $8.70 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 9.58%, resulting in a loss of $55.51 million. Via Benzinga Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting June 02, 2022 From Epizyme, Inc. Via Business Wire Stocks That Hit 52-Week Lows On Friday May 27, 2022 During Friday's session, 59 stocks hit new 52-week lows. Via Benzinga Epizyme To Participate in H.C. Wainwright Global Investment Conference May 17, 2022 From Epizyme, Inc. Via Business Wire < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.